Nebenwirkungen · Opdivo
OPDIVO 300 mg solution for injection OPDIVO 600 mg solution for injection · Abschnitt 4.8 · PDF-Seite 174
HOS-133483 · Präparat HOS-097426
In patients treated with nivolumab in combination with cabozantinib, the incidence of nephritis, immune mediated nephritis, renal failure, acute kidney injury, blood creatinine increased or blood urea increased was 10.0% (32/320). Grade 2 and Grade 3 cases were reported in 3.4% (11/320), and 1.3% (4/320) of patients, respectively. Median time to onset was 14.2 weeks (range: 2.1-87.1 weeks). Resolution occurred in 18 patients (58.1%) with a median time to resolution of 10.1 weeks (range: 0.6-90.9+ weeks).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-19T11:11:00Z · SHA-256 1ce21ede7b3b9a8abc396626f301d2db3510ede7261a38fc34a275e7a180f454 · Passage 1268772841a2db8958adb9c6512b62fe758fb7a51e09d55869076dda6d593d55 · Zeichen 43429–43938 im Abschnitt